Log in to save to my catalogue

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review...

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_387986

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

About this item

Full title

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

Publisher

London: Nature Publishing Group UK

Journal title

Nature reviews. Urology, 2019-06, Vol.16 (6), p.377-386

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III p...

Alternative Titles

Full title

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_uu_387986

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_387986

Other Identifiers

ISSN

1759-4812,1759-4820

E-ISSN

1759-4820

DOI

10.1038/s41585-019-0184-4

How to access this item